Alpha Teknova, Inc.
No SEC Form 4 filings for $TKNO in the last 30 days.
See all $TKNO insider activity →Teknova (TKNO) and Pluristyx announced the completion of a Type II Drug Master File (DMF) for PluriFreeze, a cryopreservation system, for FDA submission. The DMF supports drug makers in clinical development and manufacturing. Teknova is the exclusive U.S. and Canada distributor of PluriFreeze, which is designed for scalable manufacturing of cell-based products.
Four biotech stocks reached 52-week highs on September 23, 2026. Alpha Teknova (TKNO) hit $9.35, reporting Q2 revenue of $12.2M. Moderna (MRNA) reached $192.31 after positive clinical trial data. AtriCure (ATRC) hit $65.48 with Q2 revenue of $153.6M. Illumina (ILMN) climbed to $256.17, reporting Q2 revenue of $1.59B.
Omeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TKNO (Alpha Teknova, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent TKNO coverage spans financial news, market movers and earnings.
The DMF filing provides regulatory validation for PluriFreeze, likely supporting future sales to cell‑therapy developers and improving market perception of Teknova's product pipeline.
Price surge reflects modest revenue growth and new product launch.
Short‑term rally may be limited to the news day.
The new system could increase addressable market share and improve revenue visibility for Teknova.
Positive guidance may lift the stock as investors price in higher future profitability.
AlphAI scores every news story that mentions TKNO with an AI model for sentiment and relevance, and aggregates insider trades from Alpha Teknova, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Teknova (TKNO) and Pluristyx announced the completion of a Type II Drug Master File (DMF) for PluriFreeze, a cryopreservation system, for FDA submission. The DMF supports drug makers in clinical development and manufacturing. Teknova is the exclusive U.S. and Canada distributor of PluriFreeze, which is designed for scalable manufacturing of cell-based products.
2 min readFour biotech stocks reached 52-week highs on September 23, 2026. Alpha Teknova (TKNO) hit $9.35, reporting Q2 revenue of $12.2M. Moderna (MRNA) reached $192.31 after positive clinical trial data. AtriCure (ATRC) hit $65.48 with Q2 revenue of $153.6M. Illumina (ILMN) climbed to $256.17, reporting Q2 revenue of $1.59B.
2 min readOmeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.
2 min readAlpha Teknova (TKNO) launched Fill-Tek, a system for custom single-use bag filling, offering flexibility in sizes, quantities, and testing. The system supports 250 mL to 200 L bags and is available immediately. TKNO's stock closed at $7.11, up 3.04%, and is at $7.50 in pre-market trading.
2 min readAlpha Teknova (NASDAQ: TKNO) raised its outlook after reporting record Q2 revenue. The company expects to become adjusted EBITDA-positive in 2027 with revenue between $52M and $57M. Key growth drivers include customer progression to higher-value products and increased biopharma funding. Teknova also plans to invest in commercial capabilities and evaluate bolt-on acquisitions.
2 min readA roundup of Wall Street analyst actions includes UBS upgrading Jabil to Buy, initiating Lincoln Electric and Century Aluminum with price targets, and Bernstein initiating PDF Solutions. JPMorgan reiterates Nvidia overweight and raises CoreWeave to $110. Other changes include Loop lowering Apple to $340, Truist upgrading Best Buy to $95, and Argus upgrading Boeing to buy.
3 min readConestoga Capital Advisors’ Q2 2026 investor letter highlighted a shift toward small caps, citing Russell 2000 and Russell 2000 Growth gains. The letter said Alpha Teknova (NASDAQ:TKNO) was a top contributor, with shares at $6.53 on Aug. 6, 2026, and Clinical Solutions revenue up 85%, supported by improving biotech funding and customer activity.
6 min readAlpha Teknova, Inc. (TKNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Teknova Reports Second Quarter 2026 Financial Results Second quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior year Company raises 2026 revenue guidance to $45-47 million Launched proprietary AI-powered Build-Tek TM custom order configu
6 min readAnalyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.
7 min readThe article from MSN is incomplete and contains no meaningful content to summarize. It only provides a title and indicates it is from MSN.
1 min read
